. 2024 Mar 27;42(18):2149–2160. doi: 10.1200/JCO.23.01500

TABLE 2.

Secondary Efficacy End Points

End Point	Giredestrant (n = 151)	PCET (n = 152)
Confirmed ORR, No. (%)	19 (12.6)	11 (7.2)
95% CI	7.75 to 18.95	3.67 to 12.58
OR (95% CI)	1.87 (0.86 to 4.07)
DoR	n = 19	n = 11
Median, months (95% CI)	NR (5.55 to NE)	7.39 (7.39 to NE)
Range, months	2.0^a to 8.9^a	2.8^a to 9.3^a
CBR, No. (%)	48 (31.8)	32 (21.1)
95% CI	24.46 to 39.85	14.87 to 28.40
OR (95% CI)	1.79 (1.06 to 3.04)
OS: deaths, No. (%)	18 (11.9)	11 (7.2)
PD, No.	12	9
Grade 5 AE, No.	1^b	1^c
Other (post-treatment)	5^d	1^e

Abbreviations: AE, adverse event; CBR, clinical benefit rate; DoR, duration of response; NE, nonestimable; NR, not reached; OR, odds ratio; ORR, objective response rate; OS, overall survival; PCET, physician's choice of endocrine therapy; PD, progressive disease.

^{^a}

Censored value.

^{^b}

Ischemic stroke.

^{^c}

Pulmonary embolism.

^{^d}

Unrelated–outside of AE reporting period (>30 days post-treatment discontinuation): three COVID-19–related, two septic shocks.

^{^e}

Unrelated–outside of AE reporting period (>30 days post-treatment discontinuation): septicemia.